BACKGROUND AND PURPOSE: The aim of this study was to investigate the effect of chronic treatment with antihypertensive and non-antihypertensive doses of zofenopril on cardiovascular changes in spontaneously hypertensive rats (SHR). EXPERIMENTAL APPROACH: Male SHR were treated with 0.5 or 10 mg kg(-1) per day of zofenopril (Z(0.5) and Z(10)) for 3 months. SHR and Wistar-Kyoto rats (WKY) receiving vehicle were used as controls. Systolic blood pressure was measured using the tail cuff method. Left ventricular weight/body weight ratio was calculated as cardiac hypertrophy index. Angiotensin converting enzyme (ACE) activity was determined in plasma and tissues by a fluorimetric method. Vascular reactivity was evaluated on aortic rings by acetylcholine and sodium nitroprusside relaxations. Effects on vascular structure were assessed by lumen diameter, wall thickness and medial cross-sectional area determination. Superoxide anion generation was quantified using lucigenin-amplified chemiluminescence in aorta. RESULTS: Long-term daily administration of zofenopril (10 mg kg(-1)) to SHR reduced blood pressure to WKY values, decreased cardiac hypertrophy, improved the acetylcholine-induced relaxant response and reversed the vascular remodelling. ACE inhibition and antioxidant activity were involved in these effects. 0.5 mg kg(-1) per day of zofenopril slightly modified blood pressure and the other effects were weaker. CONCLUSIONS AND IMPLICATIONS: Antihypertensive effects of chronic treatment with zofenopril were accompanied by recovery of endothelial function and improvement of cardiovascular structure. Low-dose zofenopril had little effect on blood pressure, with some benefits on cardiovascular structure and function. Inhibition of ACE and antioxidant activity were involved in these effects.
BACKGROUND AND PURPOSE: The aim of this study was to investigate the effect of chronic treatment with antihypertensive and non-antihypertensive doses of zofenopril on cardiovascular changes in spontaneously hypertensiverats (SHR). EXPERIMENTAL APPROACH: Male SHR were treated with 0.5 or 10 mg kg(-1) per day of zofenopril (Z(0.5) and Z(10)) for 3 months. SHR and Wistar-Kyoto rats (WKY) receiving vehicle were used as controls. Systolic blood pressure was measured using the tail cuff method. Left ventricular weight/body weight ratio was calculated as cardiac hypertrophy index. Angiotensin converting enzyme (ACE) activity was determined in plasma and tissues by a fluorimetric method. Vascular reactivity was evaluated on aortic rings by acetylcholine and sodium nitroprusside relaxations. Effects on vascular structure were assessed by lumen diameter, wall thickness and medial cross-sectional area determination. Superoxide anion generation was quantified using lucigenin-amplified chemiluminescence in aorta. RESULTS: Long-term daily administration of zofenopril (10 mg kg(-1)) to SHR reduced blood pressure to WKY values, decreased cardiac hypertrophy, improved the acetylcholine-induced relaxant response and reversed the vascular remodelling. ACE inhibition and antioxidant activity were involved in these effects. 0.5 mg kg(-1) per day of zofenopril slightly modified blood pressure and the other effects were weaker. CONCLUSIONS AND IMPLICATIONS: Antihypertensive effects of chronic treatment with zofenopril were accompanied by recovery of endothelial function and improvement of cardiovascular structure. Low-dose zofenopril had little effect on blood pressure, with some benefits on cardiovascular structure and function. Inhibition of ACE and antioxidant activity were involved in these effects.
Authors: W Linz; G Wiemer; J Schaper; R Zimmermann; K Nagasawa; P Gohlke; T Unger; B A Schölkens Journal: Mol Cell Biochem Date: 1995 Jun 7-21 Impact factor: 3.396
Authors: Mark B Plotnikov; Oleg I Aliev; Aleksandr Y Shamanaev; Anastasia V Sidekhmenova; Anna M Anishchenko; Tatiana I Fomina; Victoria S Rydchenko; Andrei I Khlebnikov; Yana J Anfinogenova; Igor A Schepetkin; Dmitriy N Atochin Journal: Hypertens Res Date: 2020-05-07 Impact factor: 3.872
Authors: Lucas Giglio Colli; Larissa Berloffa Belardin; Cinthya Echem; Eliana Hiromi Akamine; Mariana Pereira Antoniassi; Rhayza Roberta Andretta; Lucas Solla Mathias; Stephen Fernandes de Paula Rodrigues; Ricardo Pimenta Bertolla; Maria Helena Catelli de Carvalho Journal: Sci Rep Date: 2019-07-30 Impact factor: 4.379
Authors: Aline R Maia; Thiago M Batista; Jamaira A Victorio; Stefano P Clerici; Maria A Delbin; Everardo M Carneiro; Ana P Davel Journal: PLoS One Date: 2014-08-29 Impact factor: 3.240
Authors: Tomas Jasenovec; Dominika Radosinska; Marta Kollarova; Peter Balis; Ezgi Dayar; Iveta Bernatova; Stefan Zorad; Norbert Vrbjar; Sona Cacanyova; Jana Radosinska Journal: Biomedicines Date: 2021-12-14